New Zealand’s PHARMAC Flip Flops On Decision To Fund Roche, Abbott Glucose Meters In Favor Of Sole Supplier
This article was originally published in PharmAsia News
Sole-supplier contracts continue to cause controversy in New Zealand, even as PHARMAC defends the practice.
You may also be interested in...
The Australian immuno-therapeutics developer Prima BioMed has had a change of focus in recent months since buying Paris-based Immutep in late 2014. Prima’s lead product used to be its CVac cancer vaccine, but it has now shifted strategic priority to an LAG-3 immune checkpoint receptor that came with the acquisition.
Phylogica is continuing its strong financial year, with the company’s shares surging after it announced that a pilot study for its cell-penetrating peptides (CPPs) showed these were able to kill drug-resistant breast cancer cells in vivo, when linked with the cancer drug Omomyc.
Australian medical device developer OncoSil Medical Limited saw its shares surge by a third on Mar. 16 after it announced that it would file for the CE Mark in both pancreatic and liver cancer indications in the second half of the year, on the back of clinical data that demonstrate its eponymous proprietary device technology is effective against two solid tumor types.